Best Pharmaceutical Stocks ASX Investors Should Know

The health care sector in Australia includes companies that create medications, sophisticated therapies and treatments for serious medical diseases. Pharmaceutical businesses can provide investors with exposure to medical innovation and long-term health care demand, but their business models and risk profiles might differ greatly.

Some firms have built global product portfolios, others are more dependent on speciality medicines, licensing deals or milestones in clinical research. ASX investors need to be able to understand pharmaceutical stocks by looking at how each firm makes money, pays for research and deals with the problems of getting therapies to the market. CSL Limited, Telix Pharmaceuticals and Neuren Pharmaceuticals are three firms to watch. Each one operates in a distinct sector of the pharmaceutical and biotech industry, providing excellent examples of how commercial scale, specialised technology and drug development might affect business possibilities.

1. CSL Limited (ASX: CSL)

CSL is a multinational biopharmaceutical firm that discovers and delivers innovative medicines that cure critical and complicated medical illnesses. The company’s business is plasma-derived therapies, vaccines and specialist medicines for fields such as immunological deficiencies, bleeding diseases and influenza prevention. Its existing manufacturing infrastructure and worldwide distribution network enable the company to serve health care markets in a number of nations. Its plasma collection and processing skills are also significant as the production of plasma-derived pharmaceuticals requires specialised facilities, quality controls and complex manufacturing processes.
 
One thing to look at from investors is whether CSL can maintain demand for existing products while developing new therapies and improving operational efficiency. Its product breadth and global footprint give it a wider commercial basis than a single-experimental-medicine company. However there are problems for CSL such as production costs, competition, changes in vaccination demand and the cost of research and development. To gauge the company’s ability to translate its scale and research capabilities into financial performance, investors should look at revenue growth, profitability, product performance and management outlook.

2. Telix Pharmaceuticals (ASX: TLX)

Telix medications focuses in radiopharmaceuticals, medications that use radioactive substances to diagnose or cure disease. Its business is the development and commercialisation of products to assist in the detection and management of diseases, particularly cancer. Drug development is mixed with specialised imaging technology and supply chain requirements in this area of medicine, which creates a distinct business model than traditional drug producers.

The potential for growth of Telix will be reliant in part on the uptake of its commercial products, expansion into additional markets and advancement across its development pipeline. Its annual statistics for 2025 showed sales of US$803.8 million, up 56% on the previous year, as well as a large investment in research and development. The firm also reported adjusted EBITDA of US$39.5 million, representing higher investment related to expansion, acquisitions and product development. These numbers emphasise the value of looking at revenue growth versus expenses and profitability, rather than making a call based just on sales numbers. 

Investors will have to examine if Telix can grow commercial use, handle production and distribution needs and advance its pipeline while controlling expenses. Future performance could be impacted by regulatory decisions, competition, clinical outcomes and our ability to get market access.

3. Neuren Pharmaceuticals (ASX: NEU)

Neuren Pharmaceuticals is a company that is developing therapies for significant neurological and neurodevelopmental illnesses including early childhood onset disorders with limited therapeutic choices. Neuren is also developing NNZ-2591, an experimental medicine in development for a range of neurodevelopmental diseases. That mix of a present-day royalty-generating product and a pipeline of research in progress offers a distinct financial profile than a company that relies solely on experimental medications. 

Its financial results may be affected by demand for its licensed medicine, royalty agreements, milestone payments and research costs. It posted royalty income of A$64.6 million in its full-year results for 2025 compared with A$56.2 million in 2024. However, total revenue and profit were lower than the prior year, in part as a major one-time milestone and other income in 2024 did not repeat in 2025. This is a good example of why investors should differentiate between recurrent income and unusual payments when evaluating the financial performance of a pharmaceutical company. 

NNZ-2591 development may bring further prospects, although there is much uncertainty in clinical studies and future commercial success is not guaranteed. Investors should look at trial progress, licensing arrangements, royalty income and what resources are needed to push research further.

What Should Investors Compare Across Pharmaceutical Stocks?

CSL, Telix and Neuren are all in the broader healthcare industry but have different financial motivations. CSL has a complicated manufacturing infrastructure and a well-established global product portfolio. Telix is combining commercial radiopharmaceutical products with ongoing investment in research and growth. Neuren is receiving royalties from a licensed medicine and is progressing its own development initiatives. Looking at share-price changes or headline revenue growth alone is not enough to compare them. 

Investors may look at revenue quality, profitability, cash reserves, research spending, regulatory milestones and dependency on certain products. Knowing how much future growth depends on established goods versus those still in the pipeline is also helpful. A corporation may have rising sales and yet be under pressure if its costs are rising even faster. Royalty income may also be subject to the commercial success of a licensing partner. Valuation matters too: a company with great products could be an expensive investment if the share price already reflects excessively positive expectations.

Risk Considerations

Clinical trial failures, regulatory delays, manufacturing problems, patent challenges and competition from alternative medicines are risks to which pharmaceutical stocks are subject. Commercial products may not meet anticipated demand and research-intensive companies may require substantial capital before new medications are able to generate revenue. Reliance on commercial partners due to licensing arrangements. Sales may be affected by changes in healthcare policy and market access. Investors must analyse the financials, product portfolio, development pipeline and valuation of each firm before making investment decisions. A good medical prospect does not automatically mean a good investment.

Disclaimer:

General Financial Product Advice and Regulatory Framework: Pristine Gaze Pty Ltd (ABN 66 680 815 678, ACN 680 815 678) operates as Corporate Authorised Representative (CAR No. 001312049) of Alpha Securities Pty Ltd (AFSL 330757), which is licensed and regulated by the Australian Securities and Investments Commission under the Corporations Act 2001 (Cth). This report contains general financial product advice only and has been prepared without consideration of your personal objectives, financial situation, specific needs, circumstances, or investment experience. The information is not tailored to individual circumstances and may not be suitable for your particular situation. Before acting on any information contained herein, you should carefully consider its appropriateness having regard to your personal objectives, financial situation, and needs, and consider seeking personal financial advice from a qualified financial adviser who can assess your individual circumstances and provide tailored recommendations.

Investment Risks and Market Warnings: All investments carry significant risk, and different investment strategies may carry varying levels of risk exposure including total loss of invested capital. The value of investments and income derived from them can fluctuate significantly due to market conditions, economic factors, company-specific events, regulatory changes, commodity price volatility, currency fluctuations, interest rate movements, and other factors beyond our control. Securities markets are subject to market risk from general economic conditions and investor sentiment, liquidity risk affecting the ability to buy or sell securities at desired prices, credit risk from issuer default or deterioration, operational risk from inadequate internal processes, sector-specific risks including industry regulatory changes, technology obsolescence, management changes, competitive pressures, supply chain disruptions, and mining-specific risks including resource estimation uncertainty, operational hazards, environmental compliance, permitting delays, commodity price cycles, geopolitical factors affecting mining operations, and exploration risks. Small-cap and speculative mining stocks carry additional risks including limited liquidity, higher volatility, dependence on key personnel, limited operating history, uncertain cash flows, and potential failure to achieve commercial production.

Information Accuracy and Limitations: While we endeavour to ensure information accuracy and reliability, we make no representations or warranties (express or implied) regarding the accuracy, reliability, completeness, timeliness, or suitability of information provided, except where liability cannot be excluded under applicable law. This report may include information from third-party sources including company announcements, regulatory filings, research reports, market data providers, financial news services, and publicly available information, which we do not independently verify and for which we assume no responsibility. Past performance, examples, historical data, or projections are not indicative of future results, and no guarantee of future returns is provided or implied. To the maximum extent permitted by law, Pristine Gaze Pty Ltd and Alpha Securities Pty Ltd, together with their respective directors, officers, employees, representatives, and related entities, exclude all liability for any errors, omissions, inaccuracies, loss or damage (including direct, indirect, consequential, or special damages) arising from reliance on information provided, investment decisions made based on this report, market losses, opportunity costs, and technical issues or system failures.